Viking Therapeutics (NASDAQ: VKTX), a biotech that has shot to prominence thanks to a weight-loss drug it is developing, was ...

Viking's leading drug candidate could be a blockbuster in the weight loss market, which experts believe could grow to $150 ...

GLP-1 drug prices are falling. That's good news for patients, but perhaps not such good news for pharmaceutical stock ...

Big pharmaceutical companies as well as smaller biotechs have been hoping to score a win in one of today's highest-growth ...

Fintel reports that on April 28, 2025, Cantor Fitzgerald initiated coverage of Viking Therapeutics (NasdaqCM:VKTX) with a ...

All that being said, until the actual clinical trial data comes out, it's impossible to say for sure that the drug will be a success, or that Viking Therapeutics stock will go up as far and as ...

The Motley Fool has positions in and recommends Pfizer. The Motley Fool recommends BioNTech Se, Novo Nordisk, and Viking Therapeutics. The Motley Fool has a disclosure policy.

Shares of NASDAQ:VKTX opened at $25.94 on Monday. The stock has a market capitalization of $2.91 billion, a PE ratio of -25.94 and a beta of 0.84. Viking Therapeutics has a 1 year low of $18.92 ...

Viking Therapeutics has a 1-year low of $18.92 and a 1-year high of $81.86. The company has a 50 day moving average price of $26.47 and a 200 day moving average price of $40.34. Insiders Place ...

Big pharmaceutical companies as well as smaller biotechs have been hoping to score a win in one of today's highest-growth treatment areas: and that's weight loss. Analysts forecast a compound ...

Viking Therapeutics (VKTX) stock rises as Pfizer (PFE) plans to bolster its pipeline with cardiometabolic and other obesity drugs, through acquisitions. Read more here.